Placebo Effect or Just Bad News? Omeros Down On OMS721 IgA Nephropathy Data

Kidney
Omeros Jarred Investors With Mixed Results In Its Phase II IgAN Study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D